V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330007160 | 330003953 | 1.63 | null | Palliative (P) | 2014-07-11 | 2014-07-31 | Rituximab | N | N | 330008012 | RITUXIMAB |
| 330007161 | 330003953 | 1.82 | null | Neo-adjuvant (N) | 2013-10-07 | 2013-10-22 | Carboplatin AUC 6 - 10 | 02 | null | 330008012 | CARBOPLATIN |
| 330007162 | 330003954 | 1.66 | 70 | Curative (C) | 2015-10-28 | 2015-10-28 | Methotrexate High Dose (3g/m2) | N | Y | 330008035 | METHOTREXATE HIGH DOSE |
| 330007163 | 330003954 | null | 55.4 | Curative (C) | 2016-07-07 | 2016-07-16 | OST Euramos 1 Closed Trial - M | 02 | N | 330008035 | METHOTREXATE HIGH DOSE |
| 330007164 | 330003956 | 1.55 | 56.9 | null | 2017-03-13 | 2017-04-01 | CISPLATIN + FLUOROURACIL | N | Y | 330008039 | CISPLATIN + FLUOROURACIL |
| 330007165 | 330003956 | null | 88.8 | Not known (9) | 2017-03-12 | 2017-05-28 | PAM x 2 post-surgery (cycles 3&4) | null | null | 330008039 | MAP |
| 330007166 | 330003957 | null | 95 | Curative (C) | 2016-03-07 | 2016-03-14 | CETUXIMAB | N | Y | 330008046 | CETUXIMAB |
| 330007167 | 330003958 | 1.77 | 84.2 | Palliative (P) | 2014-02-05 | 2014-02-05 | Etoposide + Ifosfamide (3 days) | N | N | 330008047 | ETOPOSIDE + IFOSFAMIDE |
| 330007168 | 330003960 | null | 61 | Palliative (P) | 2018-09-10 | 2018-10-16 | CISPLATIN + FLUOROURACIL | N | null | 330008049 | CISPLATIN + FLUOROURACIL |
| 330007169 | 330003962 | 1.62 | 69.5 | Curative (C) | 2013-05-25 | 2013-06-26 | OST Euramos 1 Closed Trial - M | N | Y | 330008050 | METHOTREXATE HIGH DOSE |
| 330007170 | 330003962 | 1.68 | 62.6 | Curative (C) | 2014-09-28 | 2014-10-02 | CARBOPLATIN | N | N | 330008050 | CARBOPLATIN |
| 330007171 | 330003962 | 1.66 | 64.4 | Disease modification (D) | 2015-03-26 | 2015-04-15 | Rituximab | 02 | N | 330008050 | RITUXIMAB |
| 330007172 | 330003962 | 1.32 | 75.1 | Curative (C) | 2016-11-16 | 2016-12-04 | CETUXIMAB | 2 | N | 330008050 | CETUXIMAB |
| 330007173 | 330010427 | 1.52 | 41.3 | Curative (C) | 2015-10-06 | 2015-10-26 | Carboplatin AUC 6 - 10 | 02 | N | 330008059 | CARBOPLATIN |
| 330007174 | 330010427 | 1.78 | 65.3 | null | 2016-04-07 | 2016-06-22 | Carboplatin AUC 2 - 5 | 02 | N | 330008059 | CARBOPLATIN |
| 330007175 | 330003964 | 1.79 | 72.4 | Neo-adjuvant (N) | null | 2013-11-01 | Methotrexate High Dose (3g/m2) | N | N | 330008065 | METHOTREXATE HIGH DOSE |
| 330007176 | 330010428 | 1.69 | 83 | Curative (C) | 2017-05-04 | 2017-05-12 | ETOPOSIDE + IFOSFAMIDE | null | null | 330008066 | ETOPOSIDE + IFOSFAMIDE |
| 330007177 | 330010428 | 1.77 | 47.9 | Palliative (P) | null | 2017-02-13 | ETOPOSIDE + IFOSFAMIDE | N | Y | 330008066 | ETOPOSIDE + IFOSFAMIDE |
| 330007178 | 330003965 | 1.74 | 97 | Neo-adjuvant (N) | 2013-04-19 | 2013-05-15 | Cetuximab 7 day (>Cycle 2) | 02 | null | 330008073 | CETUXIMAB |
| 330007179 | 330008158 | 1.81 | 87.3 | Adjuvant (A) | null | 2014-07-17 | Carboplatin AUC 2 - 5 | null | null | 330008073 | CARBOPLATIN |
| 330007180 | 330003966 | 1.86 | 79.5 | Palliative (P) | 2014-12-09 | 2014-12-25 | CETUXIMAB | 02 | N | 330008090 | CETUXIMAB |
| 330007181 | 330003967 | 1.8 | 87 | null | 2016-06-20 | 2016-06-25 | Carboplatin AUC 2 - 5 | 2 | Y | 330008093 | CARBOPLATIN |
| 330007182 | 330003967 | 1.59 | 60.5 | Neo-adjuvant (N) | 2014-12-20 | 2014-12-31 | CISPLATIN + FLUOROURACIL | 02 | N | 330008093 | CISPLATIN + FLUOROURACIL |
| 330007183 | 330003969 | 1.64 | 56.9 | Neo-adjuvant (N) | null | 2014-08-02 | Docetaxel + Gemcitabine (prior RT) | 02 | null | 330008095 | DOCETAXEL + GEMCITABINE |
| 330007184 | 330003970 | 1.5 | 56.3 | Adjuvant (A) | 2016-05-09 | 2016-05-21 | ETOPOSIDE + IFOSFAMIDE | Y | N | 330008102 | ETOPOSIDE + IFOSFAMIDE |
| 330007185 | 330003970 | 1.77 | null | Curative (C) | 2013-02-06 | 2013-02-08 | Rituximab (Maintenance) | 02 | N | 330008102 | RITUXIMAB |
| 330007186 | 330003971 | 1.65 | 51.2 | Palliative (P) | null | 2016-12-10 | Carboplatin AUC 2 - 5 | N | N | 330008104 | CARBOPLATIN |
| 330007187 | 330003972 | 1.8 | 81.5 | Curative (C) | 2016-05-26 | 2016-06-14 | PAM x 2 post-surgery (cycles 3&4) | 02 | Y | 330008116 | MAP |
| 330007190 | 330003979 | 0 | 115 | Curative (C) | 2018-02-16 | 2018-02-18 | OST Euramos 1 Closed Trial - M | N | N | 330008126 | METHOTREXATE HIGH DOSE |
| 330007191 | 330003981 | 1.69 | 92.7 | Neo-adjuvant (N) | 2013-11-13 | 2013-11-13 | CISPLATIN + FLUOROURACIL | null | null | 330008126 | CISPLATIN + FLUOROURACIL |
| 330007192 | 330003982 | 1.57 | 44.45 | Curative (C) | 2013-08-16 | 2014-01-24 | ETOPOSIDE + IFOSFAMIDE | 2 | Y | 330008129 | ETOPOSIDE + IFOSFAMIDE |
| 330007193 | 330003982 | 0 | 86.8 | Neo-adjuvant (N) | 2014-03-17 | 2014-06-09 | CISPLATIN + FLUOROURACIL | N | null | 330008129 | CISPLATIN + FLUOROURACIL |
| 330007194 | 330011688 | null | 69.2 | Neo-adjuvant (N) | 2016-07-27 | 2016-07-28 | OST Euramos 1 Closed Trial - M | N | null | 330008132 | METHOTREXATE HIGH DOSE |
| 330007195 | 330003984 | 1.65 | 90.6 | Curative (C) | 2017-12-04 | 2017-12-04 | Etoposide + Ifosfamide (5 days) | N | Y | 330008137 | ETOPOSIDE + IFOSFAMIDE |
| 330007196 | 330011689 | 1.81 | 115.9 | Curative (C) | 2013-05-14 | 2014-02-23 | CARBOPLATIN | N | N | 330008138 | CARBOPLATIN |
| 330007197 | 330003986 | null | null | Curative (C) | 2014-03-31 | 2014-04-11 | Docetaxel+Gemcitabine (no prior RT) | Y | N | 330008138 | DOCETAXEL + GEMCITABINE |
| 330007198 | 330003987 | null | 92.4 | null | 2014-04-09 | 2014-04-13 | Cetuximab 7 day (>Cycle 2) | Y | N | 330008146 | CETUXIMAB |
| 330007199 | 330003988 | 1.64 | null | Curative (C) | 2013-05-16 | 2013-06-12 | Carboplatin AUC 2 - 5 | null | null | 330008146 | CARBOPLATIN |
| 330007200 | 330003990 | 1.7 | 44.9 | Curative (C) | 2014-01-09 | 2014-01-09 | OST Euramos 1 Closed Trial - AP | 2 | Y | 330008152 | MAP |
| 330007201 | 330010438 | 1.62 | 59.5 | Palliative (P) | 2013-10-30 | 2013-11-23 | Cetuximab 7 day (Cycle 1) | null | N | 330008154 | CETUXIMAB |
| 330007202 | 330003992 | 1.86 | null | Curative (C) | 2018-02-18 | 2018-02-18 | Carboplatin AUC 2 - 5 | 2 | Y | 330008157 | CARBOPLATIN |
| 330007203 | 330003992 | 1.85 | 90.7 | Neo-adjuvant (N) | 2013-04-22 | 2013-05-19 | CETUXIMAB | N | Y | 330008157 | CETUXIMAB |
| 330007204 | 330003993 | 1.74 | 69 | Neo-adjuvant (N) | 2016-02-13 | 2016-03-18 | Docetaxel + Gemcitabine (prior RT) | N | N | 330008161 | DOCETAXEL + GEMCITABINE |
| 330007205 | 330008176 | 1.55 | null | Neo-adjuvant (N) | 2016-02-21 | 2016-03-10 | PAM x 2 pre-surgery (cycles 1&2) | N | N | 330008175 | MAP |
| 330007206 | 330010440 | null | 86.4 | Palliative (P) | null | 2014-12-29 | DOCETAXEL + GEMCITABINE | N | N | 330008177 | DOCETAXEL + GEMCITABINE |
| 330007207 | 330008177 | 1.69 | 89.7 | Curative (C) | null | 2013-03-16 | CARBOPLATIN | N | N | 330008178 | CARBOPLATIN |
| 330007208 | 330003995 | 1.65 | 84.6 | Palliative (P) | 2013-11-28 | 2014-04-29 | Docetaxel + Gemcitabine with GCSF | N | N | 330008180 | DOCETAXEL + GEMCITABINE |
| 330007209 | 330003995 | 1.64 | 52.3 | Curative (C) | null | 2016-04-11 | Etoposide + Ifosfamide (5 days) | null | null | 330008180 | ETOPOSIDE + IFOSFAMIDE |
| 330007210 | 330008179 | 1.74 | 82 | Curative (C) | 2015-11-13 | 2015-11-13 | Rituximab (Maintenance) | N | Y | 330008194 | RITUXIMAB |
| 330007211 | 330004003 | null | 74.4 | Palliative (P) | 2013-11-27 | 2013-11-27 | Rituximab | N | N | 330008195 | RITUXIMAB |